Management of kidney disease on cancer chemotherapy with other drugs than platinum agents

Hideki Shimodaira

Research output: Contribution to journalArticle

Abstract

Japanese clinical practice guidelines for the management of kidney disease in cancer survivors" have been published. This guideline recommended several managements for nephrotoxicity of other agents than platinum such as the urinary alkylation during methotrexate administration, suspending of anti-angiogenetic agent for the grade 2 or more proteinuria, dose modification of bisphosphonate based on the renal function. Understanding the background of these recommendations will contribute for safe cancer chemotherapy.

Original languageEnglish
Pages (from-to)204-210
Number of pages7
JournalJapanese Journal of Cancer and Chemotherapy
Volume44
Issue number3
Publication statusPublished - 2017 Mar 1

Keywords

  • Anti-angiogenesis drug
  • Bisphosphonate
  • Methotrexate
  • Renal damage

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of kidney disease on cancer chemotherapy with other drugs than platinum agents'. Together they form a unique fingerprint.

  • Cite this